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Abstract
Many nanoparticles are designed for use as potential nanomedicines for parenteral administration. However, emerging evidence suggests
that hemocompatibility is important, but is highly particle- and test-bed dependent. Thus, knowledge of bulk material properties does not
predict the hemocompatibility of uncharacterized nanoparticles, including silk nanoparticles. This study compares the hemocompatibility of
silk versus silica nanoparticles, using whole human blood under quasi-static and flow conditions. Substantial hemocompatibility differences
are noted for some nanoparticles in quasi-static versus dynamic studies; i.e., the inflammatory response to silk nanoparticles is significantly
lower under flow versus quasi-static conditions. Silk nanoparticles also have very low coagulant properties - an observation that scales from
the macro- to the nano-level. These nanoparticle hemocompatibility studies are complemented by preliminary live cell measurements to
evaluate the endocytosis and trafficking of nanoparticles in human blood cells. Overall, this study demonstrates that nanoparticle
hemocompatibility is affected by several factors, including the test bed design.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CCBY license (http://creativecommons.org/licenses/by/4.0/).
Key words: Silk; Fibroin; Silica; Blood compatibility
Nanoparticles for drug delivery were introduced in the 1970s;
Abraxane® (albumin-paclitaxel nanoparticle) was the first-
in-class drug delivery nanoparticle to entered routine clinical
use in 2005.1 This success has renewed interest in (protein)
nanoparticles as drug delivery agents, and numerous nanopar-
ticles are currently in clinical trials for a broad range of
indications, including cancer.2 Nanoparticles are attractive for
anticancer drug delivery because the endothelium within a solid
tumor is disorganized and leaky, while the tumor itself typically
has poor lymphatic drainage. These factors result in an enhanced
permeability and retention (EPR) of parenterally administered
nanomedicine within solid tumors.3,4
However, the ability of a nanomedicine to exploit the EPR
effect for tumor targeting depends on nanoparticle persistence in
the blood circulation, minimal blood activation (i.e. coagulation
and inflammation), absence of hemolysis and avoidance of
clearance by circulating monocytes and granulocytes or the
reticuloendothelial system of liver, spleen, and bone marrow.5,6
One common approach for exploiting the EPR effect and
minimizing clearance by immune cells is to surface decorate
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nanoparticles – for example, with hydrophilic poly(ethylene
glycol) (PEG) chains – to yield “stealth” nanoparticles, (reviewed
in7,8). This ‘PEGylation’ renders nanoparticles more hydrophilic,
provides steric hindrance, suppresses protein adsorption from the
plasma (for example, the FXIIa-Kallikrein-FXI activation com-
plex) and aggregation by hydrophobic interactions, thereby
increasing the nanoparticle circulation time 40- to 90-fold,
improving blood compatibility and inhibiting accumulation by
the reticuloendothelial system.6,9 Therefore assessment of “blood
performance” is a critical aspect when designing nanoparticles for
solid tumor targeting.
Pro- or anticoagulant properties of different nanoparticles and
their interaction with blood cells generally appear to be at least in
part material dependent. Nanosized particles with a diameter
below 200 nm, however, frequently have different properties
than the corresponding bulk material from which they are
derived.10 The high surface area of nanoparticles supports a
pronounced interaction with the biological environment and
typically leads to substantial protein adsorption. The conforma-
tion of the adsorbed proteins and subsequent protein–protein
interactions, in turn, are modified by the high curvature of the
nanoparticle, imparted by its small radius.11-14 For example,
polystyrene particles below 20 nm tend to prevent activation of the
intrinsic coagulation pathway, because these particles are physically
too small to allow assembly of the FXIIa-Kallikrein-FXI activation
complex. In contrast, larger particles of the same material show
strong pro-coagulant properties.11,12,14 Therefore knowledge of
bulk material properties does not predict nanoparticle blood
compatibility; as consequence nanoparticles require hemocompat-
ibility assessment.
One promising biopolymer material for nanoparticle-mediated
drug delivery is silk, which is characterized by (i) an excellent track
record in humans, (ii) unique physical properties, (iii) mild
processing conditions, (iv) the ability to adopt a broad range of
material formats, and (v) a capacity for stabilizing therapeutic
proteins and small-molecular drugs.15,16 For example, we have
recently developed macroscopic silk films,17-19 hydrogels20 and
nanoparticles21,22 for the treatment of neuroblastoma and breast
cancer. A broad range of manufacturing processes have been used
to generate silk nanoparticles; for example, milling, emulsification,
salting out, organic solvent precipitation, supercritical CO2, and
capillary microdot printing (reviewed in23). These manufacturing
approaches induce extensive β-sheets within the crystalline
regions of the silk heavy chain resulting in tightly packed and
stable silk nanoparticles.15 Silk nanoparticles generated from Bom-
byx mori, Antheraea mylitta, and recombinant spider silks 24-28
are typically endowed with an excellent drug loading capacity and
favorable pH dependent release profiles21 that can be exploited for
lysosomotropic drug delivery (reviewed in16). However, the
clinical success of any silk-based nanoparticle will depend on its
hemocompatibility.16 A number of studies have examined the
hemocompatibility of Bombyx mori silk using macroscale planar
silk surfaces.29-32 These studies have indicated minimal coagulant
but substantial complement activation.31,32 Nonetheless, a direct
transfer of the results obtained from macroscopic surfaces to
nanoparticles is not appropriate because of the previously
mentioned specific and non-typical interactions of nanoparticles
with blood.33,34 Furthermore, hemocompatibility requirements for
nanoparticles in the blood circulation appear even more stringent
than those for solid surfaces because any incompatibility reaction
of systemically administered nanoparticles would affect multiple
organs.
To date, nanoparticle hemocompatibility studies have mainly
been restricted to bare and surface-modified iron oxide,
poly(lactic-co-glycolic acid), silica, polystyrene, and carbon
nanotubes.12,14,34-36 Overall, these studies typically provide an
incomplete snapshot because (i) the measurements are performed
under static incubation conditions, which facilitates nanoparticle
aggregation, (ii) physiological shearing forces are excluded, (iii)
the measurements are performed using non-human blood, (iv)
“hemocompatibility” assessment often consists of simple
hemolysis assays, and (v) differential measurements that
interrogate the complement and coagulation cascades are
lacking.
The hemocompatibility for as yet uncharacterized nanopar-
ticles, including silk nanoparticles, remains obscure, largely due
to the limited knowledge of bulk material properties. Our aim in
the present study was to test the hemocompatibility of silk
nanoparticles (both native and PEGylated) and directly compare
their performance to that of well-characterized silica nanoparti-
cles. For these studies, we exposed human whole blood to
quasi-static conditions as well as to flow conditions that mimic
in vivo shear forces, and we complemented these studies with
single-cell live cell imaging to assess the cellular uptake of
nanoparticles.
Methods
Nanoparticles
Silica nanoparticles were purchased from NanoComposix,
Inc. (San Diego, CA, USA) as both bare and NH2 functionalized
particles with a physical diameter of 101.7 nm (± 9 nm) and
101.5 nm (± 7.4 nm), respectively. Stock suspensions in
ultrapurified water were prepared at a concentration of 5 mg/ml.
Silk nanoparticles were prepared in a one-step nanoprecipitation
procedure, as described previously21,22 and detailed in the
Supplementary Material section; for a visual protocol format
see.37 The methodologies for assessing nanoparticle size, charge,
morphology and sedimentation behavior are detailed in the
Supplementary Material.
Endotoxin testing
Surface adsorbed endotoxin was eluted from the nanoparti-
cles based on the method by Maitz38 and is detailed in the
Supplementary Material.
Human whole blood incubation assays
All studies were approved by the ethics board and complied
with institutional and international guidelines (review board of
Technische Universität Dresden, Germany). All blood donors
provided informed consent. Studies were performed with at least
one independent repeat, and both runs contained triplicate sets of
samples and donors were selected similar to previous studies31,32
and detailed in the Supplementary Material.
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Nanoparticle uptake studies using whole and fractionated blood
Endocytic uptake of fluorescently labeled nanoparticles in
whole blood was determined using a quasi-static 2 h incubation
at both 37 °C and at 4 °C. The experimental method is detailed in
the Supplementary Material.
Statistical analyses
Data analysis is detailed in the Supplementary Material.
Results
Nanoparticle characterization
Scanning electron microscopy confirmed that all nanoparticles
were spherical and had the expected sizes and surface charge (in
water): native silk nanoparticles (106.1 nm ± 0.8, zeta potential
−53 mV ± 1.7), PEGylated silk nanoparticles (116.1 nm ± 0.2,
zeta potential −43.6 mV ± 2.8), native silica nanoparticles
(101.7 nm ± 9.0, zeta potential −31.8 mV ± 0.3), and amine
functionalized silica nanoparticles (101.5 nm ± 7.4, zeta
potential −16.1 mV ± 0.6). Exposure of silk nanoparticles to
100 mM phosphate buffered saline (PBS) substantially
increased the native silk nanoparticle size over time, whereas
no changes were observed for PEGylated silk nanoparticles
(Supplementary Figure 1). Exposure of native silk nanoparticles
to 10% v/v fetal bovine serum (FBS) reduced the PBS-mediated
particle aggregation; this aggregation did not occur with
PEGylated silk nanoparticles (Supplementary Figure 1). Native
and amine-functionalized silica nanoparticles showed increased
particle size over time in response to increased buffer strength.
Inclusion of FBS reduced this apparent silica nanoparticle
aggregation (Supplementary Figure 1). Native and PEGylated
silk nanoparticles showed no signs of aggregation in water,
whereas both native and amine-functionalized nanoparticles
showed similar particle sedimentation characteristics (Supple-
mentary Figure 2). The colloidal stability of silk nanoparticles
has been reported previously.22
Endotoxin contamination of nanoparticles
Endotoxin contamination is a frequent issue with nanoparti-
cles and can confound the results of hemocompatibility
studies.38 The detergent-mediated endotoxin release from all
250 μg/ml nanoparticle suspensions was well below the reported
US Food and Drug Administration threshold value of 0.5 EU/ml
for eluates of biological products andmedical devices (Figure 1).39
Silica and silica-NH2 nanoparticles released only marginal
amounts of LPS, at 0.007 and 0.02 EU/ml, respectively. Native
and PEGylated silk nanoparticles released 0.12 EU/ml and 0.05
EU/ml, respectively. Therefore, all nanoparticle preparations were
well within the acceptable limits for LPS eluates. We spiked
nanoparticles with 0.5 EU/ml of LPS and determined subsequent
LPS recovery. Recovery for native silk nanoparticles was
complete, while PEGylated silk nanoparticles were able to quench
about 50% of the spiked LPS. Silica and silica-NH2 nanoparticles
quenched 70% and 80% of the spiked LPS, respectively.
Dose dependent effects of nanoparticles on coagulation and
inflammation
First, we examined the impact of nanoparticle dose on
hemocompatibility. Whole blood was incubated for two hours
with native silica, amine-functionalized silica, and native silk
nanoparticles at concentrations of 2.5, 25, and 250μg/ml in reaction
tubes under quasi-static conditions.Next, blood sampleswere tested
for hemostasis and inflammation biomarkers (Figure 2).
At the lowest nanoparticle concentration of 2.5 μg/ml, no
coagulation activation was detected using prothrombin F1 + 2
fragment as biomarker (Figure 2, A). At the higher nanoparticle
concentrations, the native silica nanoparticles induced a
dose-dependent increase in activation and coagulation; at a
nanoparticle concentration of 250 μg/ml silica dosed samples
were significantly different from the control (P b 0.01). This
dose-dependent activation was completely abolished for
amine-functionalized silica nanoparticles. The silk nanoparticles
induced dose-dependent coagulation activation; a significant
difference was observed at a nanoparticle concentration of 250 μg/ml
when compared to the water control (Figure 2, A).
Blood platelet activation, measured as platelet factor 4 (PF4)
release, showed only minor dose dependence for the various
nanoparticles: a 100-fold dose increase of silica or silk
nanoparticles induced a 2.6- and 2.8-fold increase of PF4
release, respectively (Figure 2, B). Aminated silica nanoparticles
did not activate blood platelets but instead appeared to suppress
platelet activity at high nanoparticle concentrations. In contrast,
native silk nanoparticles showed significant dose dependent
platelet activation when compared to the controls. PF4 release
correlated well with the decay of blood platelets during the
incubation (Supplementary Figure 3).
The C5a fragment of the common complement pathway was
measured and served as a total complement activation marker (i.e.
without discriminating its initiation by the classical or alternative
route). Complement activation exhibited only minor dose
dependence for all studied nanoparticles: the C5a level increased
only two-fold for aminated silica and native silk nanoparticles and
four-fold for native silica nanoparticles, despite a 100-fold increase
Figure 1. Endotoxin contamination of nanoparticles. Amount of lipopoly-
saccharides (LPS) extracted from 250 μg nanoparticle samples using a 1 ml
aqueous 0.2% v/v Tween-20 extraction buffer. LPS recovery for nanopar-
ticles spiked with 0.5 EU LPS. The threshold for eluates from medical
devices has a limit of 0.5 EU/ml. (mean ± SD, n = 2 independent
measurements).
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in nanoparticle concentration (Figure 2C). No significant differ-
ences were noted in complement activation between native and
amine-functionalized silica. In contrast, native silk particles
showed a 10-fold higher complement activation than the control,
although silk nanoparticles showed no significant dose dependence
in the analyzed range. In agreement with complement activation
results (Figure 2,C), leukocyte activation,measured as granulocyte
CD11b expression (Figure 2, D), was elevated in response to
addition of silk nanoparticles but showed no dose dependence for
any of the tested nanoparticles.
The high baseline platelet and inflammatory activation
observed for native silk nanoparticles was not attributable to
compound(s) and/or contaminants that could be readily leached
from silk nanoparticles, because collection and analysis of the
final washing fraction generated during silk nanoparticle
preparation did not induce this activation (Figure 3). Indeed,
Figure 2. Activation of hemostasis and inflammation parameters of human whole blood in response to different nanoparticle concentrations. Nanoparticles were
added to 1.5 U/ml heparinized blood and incubated for 2 h under quasi-static incubation conditions while avoiding sample sedimentation. (A) Prothrombin
fragment F1 + 2 as a marker for plasmatic coagulation. (B) Platelet factor 4 (PF4) as a marker for platelet activation. (C) Complement fragment C5a as a marker
for complement activation. (D) Granulocyte CD11b expression as a marker for leukocyte activation. Vehicle: ultrapure water; the continuous phase used for
nanoparticle preparations. Mean ± SD of n = 6; asterisks indicate significant difference to the water control (*: P b 0.05; **: P b 0.01).
Figure 3. Impact of PEGylation on silk nanoparticle hemocompatibility. Activating effect of silk nanoparticles (250 μg/ml) on human whole blood.
Nanoparticles were added to 1.5 U/ml heparinized blood and incubated for 2 hours under quasi-static incubation conditions while avoiding sample
sedimentation. Hemostatic activity (F1 + 2 fragment and PF4 release, panels A and B, respectively) and pro-inflammatory response (C5a and granulocyte
activation, panels C and D, respectively) of native and PEGylated silk nanoparticles. The final aqueous washing fraction generated during silk nanoparticle
preparation. Vehicle: ultrapure water; the continuous phase used for nanoparticle preparations. (mean ± SD of n = 6).
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this washing fraction induced a similar biological response to the
one observed for ultrapure water (Figure 3). Therefore, native
silk nanoparticles were PEGylated to provide further improve-
ment in silk nanoparticle hemocompatibility. PEGylation
suppressed the pro-coagulant characteristics of silk nanoparticles
from the pre-existing low level to the levels seen for negative
control samples (Figure 3, A). Furthermore, silk nanoparticle
PEGylation significantly suppressed blood platelet activation
(P b 0.01) to levels comparable to controls (Figure 3, A and B).
However, levels of the inflammatory markers (C5a fragments and
granulocyte CD11b expression) remained high and were not
significantly affected by surface decoration of the silk nanoparticles
with 5000 g/mol ethoxypolyethylene glycol (Figure 3, C and D).
Nanoparticle uptake using whole and fractionated blood
Flow cytometry of human whole blood after incubation with
fluorescently labeled silk nanoparticles showed cell-associated
fluorescence for granulocytes (dim) and monocytes (bright)
(Figure 4, A). PEGylated silk nanoparticles behaved similarly to
native silk nanoparticles. Blood samples incubated with
fluorescently labeled aminated silica nanoparticles showed
lower cell-associated fluorescence when compared to samples
incubated with silk nanoparticles. Furthermore, monocytes
incubated with aminated silica nanoparticles appeared brighter
than granulocytes (Figure 4, A).
Measurements of cell-associated fluorescence by flow
cytometry typically do not permit differentiation of internalized
(i.e., endocytosed) and non-specific plasma membrane adsorbed
nanoparticles. Therefore, in parallel experiments, cells were
incubated on ice together with native silk nanoparticles to
estimate plasma membrane adsorption of nanoparticles.
Four-fold higher numbers of fluorescent cells were observed
when incubation was conducted at 37 °C than at 4 °C. Despite
the differences in the fluorescence intensity between monocytes
and granulocytes (Figure 4, A, left graph), no significant
difference was noted in the percentage of positive and negative
cells at the respective temperatures (Figure 4, A, right graph).
Flow cytometry studies were supplemented using live cell
fluorescence microscopy of isolated monocytes (Figures 4 and 5).
Here, time-lapse studies indicated that native silk nanoparticles
started to form microsized aggregates (Figure 5, B) in culture and
that these aggregates were taken up by monocytes and
subsequently released (Figure 5, A) or retained (Figure 5, B and
Supplementary movie 1). Some of these retained silk nanoparticle
aggregates were trafficked to acidic vesicles (Figure 4, B) within
30 minutes (time-lapse data not shown). The behavior of
PEGylated silk nanoparticles differed markedly from that of the
native silk nanoparticles, showing less nanoparticle aggregation
during the course of the study. In particular PEGylated silk
nanoparticles showed vesicular labeling throughout monocyte
cytoplasm, in addition to some co-localization with acidic vesicles
(Figure 4, C).
Shear flow incubation of nanoparticles with whole blood
The quasi-static blood incubation studies were complemented
by blood compatibility studies of the nanoparticles under shear
conditions in an attempt to better mimic the in vivo scenario.
Therefore, blood was incubated with 250 μg/ml nanoparticles in a
Chandler loop setup40 at a flow rate of 12 cm/s. Both hemostasis
and inflammation biomarkers were monitored and directly
compared to the quasi-static incubation setup (Figure 6, A).
Many of the datasets for the quasi-static and the Chandler
loop experiments were similar. For example, native silica
nanoparticles had a high coagulation activation (prothrombin
F1 + 2 levels) that was suppressed to baseline levels through
silica amination (Figure 6, B). This high coagulation activation
of native silica nanoparticles was significantly greater than the
activation seen for either the native or PEGylated silk
nanoparticles (Figure 6, B). Under both quasi-static and flow
conditions, native silk nanoparticles showed high levels of
platelet activation that was matched by the decay in platelet
Figure 4. Cellular uptake of silk nanoparticles. (A) Nanoparticles were
incubated with human whole blood for 2 h and cell-associated fluorescence
of granulocytes and monocytes was assessed by flow cytometry. Silk-
nanoparticle positive cells after 2 h incubation with native silk nanoparticles
at 37 °C and 4 °C. The 4 °C studies were conducted to estimate plasma
membrane nanoparticle binding. Statistically significant differences between
samples are indicated by a horizontal line with asterisk (P b 0.05; mean ±
SD of n = 6). Live cell confocal slices (i–iii) of isolated monocytes
incubated for 2 h with (B) native and (C) PEGylated silk nanoparticles.
Lysosomes were stained red and silk preparations were green. Open arrows
denote single color vesicles (red or green) and closed arrows co-localization
(yellow). Scale bar 10 μm.
2637M.F. Maitz et al / Nanomedicine: Nanotechnology, Biology, and Medicine 13 (2017) 2633–2642
numbers in whole blood (Figure 6, C, Supplementary Figure 4).
Notably, platelet activation under flow conditions was compa-
rable for both native silk and silica. However, the blood platelet
activation seen with silk nanoparticles was significantly
suppressed when PEGylated silk nanoparticles were tested
under both conditions (Figure 6, C). Assessment of CD11b as
a marker for granulocyte activation showed similar activation
levels for silica nanoparticles and vehicle controls under both
quasi-static and flow conditions (Figure 6, E). Elevated CD11b
levels, were observed for native and PEGylated silk nanoparti-
cles when compared to vehicle controls.
Nevertheless, some striking differences in the results were
observed for the two incubation modes: The shear conditions
typically induced higher blood platelet activation, based on the
PF4 marker (Figure 6, C). However, the already very high
expression levels of PF4 for native silk nanoparticles under
quasi-static conditions resulted in little change under flow
conditions. In contrast, the high C5a levels induced by native and
PEGylated silk under static conditions were significantly
reduced under flow conditions, with little overall change in
C5a levels observed for controls and silica, where the C5a levels
were already low under static conditions (Figure 6, D).
Furthermore, under quasi-static conditions native silk nanopar-
ticles showed substantially higher Prothrombin-fragment F1 + 2
than under flow conditions (Figure 6, B).
The flow incubation was also performed with fluorescently
labeled silk nanoparticles. Here, monocytes were subsequently
isolated and imaged by fluorescence microscopy (Figure 7).
Here, studies with native silk nanoparticles resulted in a loss of
monocytes, so that these cells could not be isolated and imaged.
However, microscopy of the PEGylated silk nanoparticles
showed co-localization of the nanoparticles in lysosomes.
Discussion
Hemocompatibility testing of “nanomedicine” is typically
performed under static conditions, often using non-human
fractionated blood coupled with endpoint measures, such as
hemolysis. These types of studies can be useful for initial screening
purposes and provide a first indication of the nanomedicine–blood
interaction.33,34 However, the absence of hemolysis in these
studies is often used to classify novel nanomedicine as
“hemocompatible”; this undermines our current understanding of
hemocompatibility and with potentially deleterious consequences.
Note that no hemolysis was evident for the silk nanoparticles
studied here aswell asmacroscopic silk films.29-32Adirect transfer
of hemocompatibility properties from the macroscopic material to
their nanosized counterparts also is not appropriate. We therefore
selected 100 nm nanoparticles for this study because this size is
particularly relevant for anticancer nanomedicines. For example,
emerging (e.g., BIND-014) and clinically used anticancer
nanomedicines (e.g., Doxil) are within this 100 nm size range,
while larger nanoparticles (e.g., N200 nm) are currently not
undergoing clinical development because the optimum nanopar-
ticle size for solid tumor targeting via the EPR effect is in the 100
nm size range and below.2
Some isolated hemostasis or inflammatory reactions have been
reported for nanoparticles in general,34 but these studies typically
disregard the interplay of inflammatory and hemostatic, humoral,
Figure 5. Time-lapse microscopy of a single human monocyte exposed to native silk nanoparticles. (A) Time dependent uptake and subsequent release of silk
nanoparticle aggregate (closed black arrow). (B) Retention of a silk nanoparticle aggregate by a monocyte. White arrows show plasma membrane ruffling and
subsequent phagocytosis of silk. Monocyte shown in (A) and (B) is the same cell; images are montages of phase contrast and epifluorescent images of a cell and
silk (green), respectively. Scale bar 10 μm.
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and cellular systems as well as the impact of flow conditions.
Hemocompatibility testing of nanoparticles rarely includes the use
of human whole blood and flow conditions.41 In the current study,
our aim was to compare our well established human whole blood
hemocompatibility setup42,43 with a state-of-the-art dynamic
incubation protocol and live cell imaging. We used these test
systems to compare the inflammatory and hemostasis response of
novel silk nanoparticles and previously well-characterized silica
nanoparticles.
We and others have recently reported the use of silk
nanoparticles for anticancer drug delivery, in particular for
targeting to solid tumors21,22,27,44 and their ability to reprogram
macrophage metabolism.45 However, little is known about silk
nanoparticle performance in the bloodstream. We therefore
assessed native and PEGylated silk nanoparticles and compared
their performance directly with well-established silica nanopar-
ticles using a range of test systems. Native silk nanoparticles, at
the lowest concentration of 2.5 μg/ml, induced higher blood
platelet (PF4), leukocyte (CD11b expression) and complement
(C5a) activation than was observed in the blank control, whereas
native and aminated silica nanoparticles at this concentration
induced activation levels similar to the control (Figure 2). In a
separate set of studies, where all nanoparticles were subjected to
a washing protocol to estimate the potential contribution of LPS
contamination to overall hemocompatibility, the observed blood
activation was a direct consequence of the nanoparticles and was
not due to elution of soluble substances (Figure 1).
The maximum nanoparticle concentration used in the present
studywas 250 μg/ml; this concentrationwas based on estimates for
using silk nanoparticles as a doxorubicin drug delivery system (i.e.,
40 ng doxorubicin/μg silk). Assuming a human blood volume of 5
liters, a nanoparticle concentration of 250 μg/ml is a reasonable
estimate at steady state. We used the maximum concentration of
250 μg/ml and tested the dose dependence of coagulant and
inflammatory responses of nanoparticles over two orders of
magnitude. For all parameters tested, only a sublinear responsewas
observed. At most, the 100-fold increase in silica nanoparticle
concentration caused a 40-fold increase in the thrombin activation
(Figure 2, A). For other parameters and other materials, the
increase was less significant. We compared nanoparticle perfor-
mance based on mass rather than nanoparticle numbers. When
based on the nanoparticle numbers, we used approximately 30%
more silk nanoparticles than silica nanoparticles. Dose–response
studies indicated that, typically, a N 200% increase in nanoparticle
number was required to induce any substantial biological change
(Figure 2).
Figure 6. Impact of flow on nanoparticle hemocompatibility in human whole blood. (A) Scheme of the flow and quasi-static setup. A flow of 12 cm/s was
obtained in a rotating closed loop system (Chandler loop); the quasi-static incubation was conducted in reaction tubes under constant overhead rotation. (B–E)
Coagulation and inflammation activation of whole blood dosed with nanoparticles and incubated for 2 h under flow or quasi-static conditions.
Prothrombin-fragment F1 + 2, platelet factor 4 (PF4), complement C5a concentration, and granulocyte CD11b expression level were used as biomarkers for
blood activation. Mean ± SD of n ≥ 6. Asterisks above a column indicate significant difference to the water blank; differences between samples are indicated by
a horizontal line with asterisk (P b 0.05).
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A potential caveat of our study is that we cannot exclude the
possibility of nanoparticle aggregation decreasing the effective
surface area (Supplementary Figures 1 and 2), thereby leading to
the non-linear response. High PF4 and C5a levels observed over
the particle concentration test range might indicate saturation
and/or exhaustion.
Different types of nanoparticles and nanotubes activate blood
platelets at concentrations above 20 μg/ml via a plasma membrane
Ca2+ flux dependent pathway.46,47 Lower concentrations of the
nanoparticles sensitize platelets to thromboxane (TxA2) and
ADP.46 The results reported here for native silica particles were
in good agreement with the literature, whereas the threshold for
native silk nanoparticles to induce blood platelet activation
appeared to be below 2.5 μg/ml. Thrombin generally is the
strongest activator of blood platelets, and platelet activation in
hemocompatibility tests typically closely correlates with thrombin
formation. The current study strongly suggests that the native silk
nanoparticles activated platelets directly, because thrombin
formation was not observed (Figure 3).
Despite a number of blood studies examining silk
hemocompatibility29-32 the underlying mechanism(s) of cell
and humoral pathway activation by silk remains to be elucidated.
Previous studies using macroscopic silk films also demonstrated
that silk directly activated platelets.31,32 Notably, the overall
blood compatibility performance was not dependent on a single
factor (e.g., silk secondary structure), but on a multitude of
processing parameters.32 We therefore cannot speculate which
silk nanoparticle feature contributes to its overall hemocompat-
ibility performance.
Silk is known for inducing a mild inflammatory response
in vivo.48 We previously observed a substantial in vitro
complement activation of the alternative pathway with macro-
scopic silk films and human whole blood.31,32 Complement
activation requires the assembly of multi-enzyme complexes on
the foreign surface. Several studies have shown that complement
activation by IgM via the classical pathway is geometrically
hindered on small nanoparticles with diameters below 250 nm,
because for these particles the curvature is too high and the
available area too small for the assembly of the complement
complexes.49,50 Few studies have examined the ability of
nanoparticles to activate the complement system via the alternative
pathway. The initiator of this alternative pathway, C3b, occupies a
surface area of 40 nm2, suggesting that a relatively large particle
with sufficient surface area is required for the successful activation
of the complement cascade and propagation to the membrane
attack complex.49,51 In the present study, silk nanoparticles
induced high complement activation during static incubation, but
complement activation was significantly suppressed in the
Chandler-loop incubation (Figure 5). This may be evidence of
nanoparticle aggregation during the static incubation, where large
nanoparticle agglomerates could be supporting the propagation of
the complement cascade. In contrast, in the dynamic studies, the
particles conceivably could have remained more dispersed
(Supplementary Figures 1 and 2) and the complement cascade
did not proceed to completion.
Strong complement activation by nanoparticles may pose a
problem for their routine application as nanomedicine, as it may
cause complement-dependent allergic reactions that in turn
necessitate pre-treatment with steroids.52 The present study
suggests that this systemic effect would be absent for silk
nanoparticles, as the complement activation under flowing
conditions was substantially diminished. However, aggregation
of nanoparticles remains a conceivable possibility in the
extracellular space of solid tumors, with the potential to activate
the complement system there. Induction of complement
activation via anticancer nanomedicine is a significant problem,
because the C5a anaphylatoxin is known to stimulate tumor
growth by suppression of CD8 T-cells.53-55 In turn, blockage of
C5a signaling decreases tumor growth with efficiency similar to
that of paclitaxel-based anticancer treatment.53 Therefore,
minimizing nanoparticle aggregation is critical for their devel-
opment as nanomedicine.
Stealth technologies such as PEGylation are typically used to
prevent nanoparticle aggregation and to minimize their detri-
mental interactions with biological systems. In the present study,
PEGylated silk nanoparticles efficiently suppressed coagulation
and blood platelet activation (Figure 3, A and B). Furthermore,
PEGylated silk nanoparticles also showed less aggregation under
static conditions (Figure 4, C). Nevertheless, complement and
leukocyte activation persisted, although complement-activating
free hydroxyl groups were avoided with the use of mono-
methoxy terminated PEG.22,42 PEGylation not only improves
colloidal stability22 and blood compatibility, but it also reduces
serum protein adsorption. Consequently, PEGylated silk
Figure 7. Impact of flow on PEGylated silk nanoparticle uptake and
trafficking in human whole blood. Whole blood was incubated with
PEGylated silk nanoparticles for 2 h under dynamic conditions followed
by immediate monocyte isolation, lysosome staining and imaging of live
cells. Lysosomes were stained red and PEGylated silk nanoparticles were
green. Open arrows denote single color vesicles (red or green) and closed
arrows co-localization (yellow). Images are montages of phase contrast and
confocal slices at two focal planes. Scale bar 5 μm.
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nanoparticles are expected to have a reduced and/or different
biomolecular corona when compared to native silk nanoparticles.
This biomolecular corona is expected to influence (silk)
nanoparticle performance.56 However, little is known at present
regarding the extent and the composition of the biomolecular
corona for silk nanoparticles.
In whole blood, both silica and silk nanoparticles were
actively taken up by granulocytes and monocytes, with
monocytes showing the highest nanoparticle uptake (Figure 4).
However, the low abundance of monocytes in the blood meant
that only approximately 20% of the total nanoparticle uptake
could be attributed to those cells. The literature examining
nanoparticle uptake by blood cells is sparse: monocytes are
frequently seen as the most important cell type responsible for
nanoparticle uptake in blood and are thus considered during
(nano)particle design.57 Granulocytes, by contrast, are rarely the
focus of attention when designing novel nanomedicines.58 We
attempted to differentiate between plasma membrane associated
nanoparticle fluorescence and endocytosed nanoparticles by
performing incubation studies at 4°C and 37°C, respectively.
The incubation studies on ice verified that the majority of
cell-associated fluorescence was due to active uptake by the cells
rather than non-specific plasma membrane binding of nanopar-
ticles; this was independent of the cell type.
Endocytic uptake was also verified by live cell fluorescence
microscopy studies using both native and PEGylated silk
nanoparticles and isolated monocytes. The PEGylated silk
nanoparticles showed clear evidence of an endocytic accumu-
lation into acidic, LysoTracker positive vesicles, which were
most likely lysosomes. This intracellular pattern of silk
nanoparticle accumulation correlates well with studies that
examined endocytosis of silk nanoparticles in breast cancer
cells.21,22 However, the exact endocytic uptake mechanism(s) by
human monocytes remains to be determined.16
Many nanomedicines are traditionally designed for targeting
of solid tumors, and especially cancer cells. However, we have
demonstrated here that they can directly interact with subpop-
ulations of blood cells. Therefore, nanoparticles can conceivably
evoke unintended responses in these cells during their journey to
their final tumor destinations. Alternatively, recent evidence
suggests that particulate-mediated immune modulation of
inflammatory monocytes can be exploited to moderate inflam-
matory responses in a broad spectrum of diseases.59 Thus the
appropriate design of a particulate (nano)medicine is critical to
achieve the intended outcome.60
We demonstrated substantial differences for selected nano-
medicines in quasi-static and dynamic hemocompatibility
studies. In particular, the inflammatory response was signifi-
cantly reduced for silk nanoparticles under dynamic conditions
when compared to the quasi-static setup. Furthermore, we
demonstrated that the silk nanoparticles had very low procoa-
gulant properties, an observation that was scalable from the
macroscopic level of planar surfaces to the nano-level.32
Hemocompatibility studies using silica and silk nanoparticles
were complemented by preliminary live cell measurements to
provide a first insight into the endocytosis and trafficking of
these particles in blood cells. Overall, this study demonstrates
that a multitude of factors affect hemocompatibility; thus, the
design of the most appropriate test bed for hemocompatibility
studies is highly application dependent.
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